Acetyl-L-carnitine ameliorates atherosclerosis in LDLR<sup>-/-</sup> mice by modulating cholesterol metabolism through SREBP2-dependent cholesterol biosynthesis.

Front Nutr · 2024 · PMC11684389 · PMID 39737151

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

FPLC analysis revealed that plasma LDL-C in the HCD + ALC group exhibited a decreasing trend, whereas HDL-C showed an increasing trend ( Figure 2D ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Acetyl-L-carnitine ameliorates atherosclerosis in LDLR&lt;sup&gt;-/-&lt;/sup&gt; mice by modulating cholesterol metabolism through SREBP2-dependent cholesterol biosynthesis.

The sentences

Acetyl-L-carnitine ameliorates atherosclerosis in LDLR<sup>-/-</sup> mice by modulating cholesterol metabolism through SREBP2-dependent cholesterol biosynthesis.